Broad-spectrum antibiotic use and poor outcomes in community-onset pneumonia: A cohort study.
The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Abstract
Question: Is broad-spectrum antibiotic use associated with poor outcomes in community-onset pneumonia after adjusting for confounders? Methods: We performed a retrospective, observational cohort study of 1995 adults with pneumonia admitted from four US hospital emergency departments. We used multivariable regressions to investigate the effect of broad-spectrum antibiotics on 30-day mortality, length of stay, cost and Clostridioides difficile infection (CDI). To address indication bias, we developed a propensity score using multilevel (individual provider) generalised linear mixed models to perform inverse-probability of treatment weighting (IPTW) to estimate the average treatment effect in the treated. We also manually reviewed a sample of mortality cases for antibiotic-associated adverse events. Results: 39.7% of patients received broad-spectrum antibiotics, but drug-resistant pathogens were recovered in only 3%. Broad-spectrum antibiotics were associated with increased mortality in both the unweighted multivariable model (OR 3.8, 95% CI 2.5–5.9; p<0.001) and IPTW analysis (OR 4.6, 95% CI 2.9–7.5; p<0.001). Broad-spectrum antibiotic use by either analysis was also associated with longer hospital stay, greater cost and increased CDI. Healthcare-associated pneumonia was not associated with mortality independent of broad-spectrum antibiotic use. In manual review we identified antibiotic-associated events in 17.5% of mortality cases. Conclusion: Broad-spectrum antibiotics appear to be associated with increased mortality and other poor outcomes in community-onset pneumonia.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Among undifferentiated patients with pneumonia or sepsis, broad-spectrum regimens including agents active against MRSA were associated with higher mortality, particularly among patients without MRSA [137, 151, 155, 156].”
From Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021 (2021) · cites this paper as [156]
Citations
Cites
Surviving Sepsis Campaign: International Guidelines for Management of Severe Sepsis and Septic Shock
Dellinger, R. P., Levy, M. M., Rhodes, A., Annane, D., Gerlach, H., Opal, S. M., Sevransky, J. E., Sprung, C. L., Douglas, I. S., Jaeschke, R., et al. (2013) · Critical Care Medicine · doi:10.1097/ccm.0b013e31827e83af · Cited by 9,694
Dellinger, R. P., Levy, M. M., Carlet, J. M., Bion, J., Parker, M. M., Jaeschke, R., Reinhart, K., Angus, D. C., Brun-Buisson, C., Beale, R., et al. (2008) · Intensive Care Medicine · doi:10.1007/s00134-007-0934-2 · Cited by 6,772
Mandell, L. A., Wunderink, R. G., Anzueto, A., Bartlett, J. G., Campbell, G. D., Dean, N. C., Dowell, S. F., File, T. M., Musher, D. M., Niederman, M. S., et al. (2007) · Clinical Infectious Diseases · doi:10.1086/511159 · Cited by 6,202
Self-citation(2005) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.200405-644st · Cited by 5,877
Austin, P. C., & Stuart, E. A. (2015) · Statistics in Medicine · doi:10.1002/sim.6607 · Cited by 4,495
Generalized Additive Models for Location Scale and Shape (GAMLSS) in R
Stasinopoulos, D. M., & Rigby, R. A. (2007) · Journal of Statistical Software · doi:10.18637/jss.v023.i07 · Cited by 1,560
Emergency Department Visits for Antibiotic‐Associated Adverse Events
Shehab, N., Patel, P. R., Srinivasan, A., & Budnitz, D. S. (2008) · Clinical Infectious Diseases · doi:10.1086/591126 · Cited by 535
Estimating National Trends in Inpatient Antibiotic Use Among US Hospitals From 2006 to 2012
Baggs, J., Fridkin, S. K., Pollack, L. A., Srinivasan, A., & Jernigan, J. A. (2016) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2016.5651 · Cited by 268
Chalmers, J. D., Rother, C., Salih, W., & Ewig, S. (2014) · Clinical Infectious Diseases · doi:10.1093/cid/cit734 · Cited by 251
Luther, M. K., Timbrook, T. T., Caffrey, A. R., Dosa, D., Lodise, T. P., & LaPlante, K. L. (2018) · Critical Care Medicine · doi:10.1097/ccm.0000000000002769 · Cited by 235
Research works printed but not linked: 1
- Mecham ID, 2018, The association of qSOFA, SOFA and SIRSA with mortality in emergency department pneumonia patients, J Respir Infect, 97, e12634
Cited by
Surviving sepsis campaign: international guidelines for management of sepsis and septic shock 2021
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Intensive Care Medicine · doi:10.1007/s00134-021-06506-y · Cited by 5,082
Surviving Sepsis Campaign: International Guidelines for Management of Sepsis and Septic Shock 2021.
Evans, L., Rhodes, A., Alhazzani, W., Antonelli, M., Coopersmith, C. M., French, C., Machado, F. R., Mcintyre, L., Ostermann, M., Prescott, H. C., et al. (2021) · Critical Care Medicine · doi:10.1097/ccm.0000000000005337 · Cited by 2,935
Rhee, C., Kadri, S. S., Dekker, J. P., Danner, R. L., Chen, H.-C., Fram, D., Zhang, F., Wang, R., Klompas, M., & Program, F. T. C. P. E. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.2899 · Cited by 397
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
Martin-Loeches, I., Torres, A., Nagavci, B., Aliberti, S., Antonelli, M., Bassetti, M., Bos, L. D., Chalmers, J. D., Derde, L., de Waele, J., et al. (2023) · Intensive Care Medicine · doi:10.1007/s00134-023-07033-8 · Cited by 316
“Logistics on how testing can be continuously available, and results reported, is a major implementation consideration.”
Aliberti, S., Dela Cruz, C. S., Amati, F., Sotgiu, G., & Restrepo, M. I. (2021) · The Lancet · doi:10.1016/s0140-6736(21)00630-9 · Cited by 305
ERS/ESICM/ESCMID/ALAT guidelines for the management of severe community-acquired pneumonia
Martín‐Loeches, I., Torres, A., Nagavci, B., Aliberti, S., Antonelli, M. M., Bassetti, M., Bos, L. D. J., Chalmers, J. D., Derde, L. P. G., Waele, J. J. D., et al. (2023) · European Respiratory Journal · doi:10.1183/13993003.00735-2022 · Cited by 199
Management of pneumonia in critically ill patients
Cillóniz, C., Torres, A., & Niederman, M. S. (2021) · BMJ · doi:10.1136/bmj-2021-065871 · Cited by 171
Timing of antibiotic therapy in the ICU
Kollef, M. H., Shorr, A. F., Bassetti, M., Timsit, J.-F., Micek, S. T., Michelson, A. P., & Garnacho-Montero, J. (2021) · Critical Care · doi:10.1186/s13054-021-03787-z · Cited by 161
“7% received broad-spectrum antibiotics, but MDRB were recovered in only 3% [16].”
BackgroundJones, B. E., Ying, J., Stevens, V., Haroldsen, C., He, T., Nevers, M., Christensen, M. A., Nelson, R. E., Stoddard, G. J., Sauer, B. C., et al. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.7495 · Cited by 122
Zasowski, E. J., Bassetti, M., Blasi, F., Goossens, H., Rello, J., Sotgiu, G., Tavoschi, L., Arber, M. R., McCool, R., Patterson, J. V., et al. (2020) · Chest · doi:10.1016/j.chest.2020.03.087 · Cited by 117
Reynolds, D., Burnham, J. P., Guillamet, C. V., McCabe, M., Yuenger, V., Betthauser, K. D., Micek, S. T., & Kollef, M. H. (2022) · European Respiratory Review · doi:10.1183/16000617.0068-2022 · Cited by 113
Evaluation of the Biofire Filmarray Pneumonia panel plus for lower respiratory tract infections
Edin, A., Eilers, H., & Allard, A. (2020) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2020.1755053 · Cited by 79
“On the contrary, broad-spectrum antimicrobial treatment have been identified as an independent risk factor for both increased mortality and complications, such as Clostridium difficile infection, in hospital-treated patients [12].”
BackgroundPletz, M. W., Blasi, F., Chalmers, J. D., Cruz, C. S. D., Feldman, C. H., Luna, C. M., Ramírez, J. A., Shindo, Y., Stolz, D., Torres, A., et al. (2020) · CHEST Journal · doi:10.1016/j.chest.2020.07.089 · Cited by 79
Self-citationGinocchio, C. C., Garcia-Mondragon, C., Mauerhofer, B., Rindlisbacher, C., Collaborative, A. T. E. E. P., Forcelledo, L., Fernández, J., Lienhard, R., Kerschner, H., Rossolini, G. M., et al. (2021) · European Journal of Clinical Microbiology & Infectious Diseases · doi:10.1007/s10096-021-04195-5 · Cited by 74
on behalf of JAAM FORECAST group, Abe, T., Kushimoto, S., Tokuda, Y., Phillips, G. S., Rhodes, A., Sugiyama, T., Komori, A., Iriyama, H., Ogura, H., et al. (2019) · Critical Care · doi:10.1186/s13054-019-2644-x · Cited by 73
Management of Sepsis and Septic Shock: What Have We Learned in the Last Two Decades?
Kamath, S., Altaq, H. H., & Abdo, T. (2023) · Microorganisms · doi:10.3390/microorganisms11092231 · Cited by 69
Falsey, A. R., Branche, A. R., Croft, D. P., Formica, M. A., Peasley, M., & Walsh, E. E. (2023) · The Journal of Infectious Diseases · doi:10.1093/infdis/jiad221 · Cited by 65
Cartuliares, M. B., Rosenvinge, F. S., Mogensen, C. B., Skovsted, T. A., Andersen, S. L., Østergaard, C., Pedersen, A. K., & Skjøt‐Arkil, H. (2023) · PLoS Medicine · doi:10.1371/journal.pmed.1004314 · Cited by 53
Zhang, J., Yan, W., Dong, Y., Luo, X., Miao, H., Maimaijuma, T., Xu, X., Jiang, H., Huang, Z., Qi, L., et al. (2024) · Journal of Thoracic Disease · doi:10.21037/jtd-24-1191 · Cited by 53
“Still other research suggests that the use of drugs to treat MRSA in patients with sepsis is associated with higher mortality rates, especially in patients without MRSA (138-141).”
Impact of Multiplex PCR in the Therapeutic Management of Severe Bacterial Pneumonia
Dessajan, J., & Timsit, J. (2024) · Antibiotics · doi:10.3390/antibiotics13010095 · Cited by 47
“In CAP, unnecessarily broad-spectrum antimicrobial therapy has also been shown to be associated with increased mortality, longer length of stay, and higher costs when compared to narrow-spectrum antimicrobial therapy [9].”
BackgroundAntibiotic therapy for severe bacterial infections
Timsit, J., Ling, L., de Montmollin, É., Bracht, H., Morris, A. C., Bus, L. D., Falcone, M., Harris, P. N. A., Machado, F. R., Paiva, J.-A., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08063-0 · Cited by 47
“In CAP, one-third of cases receive overly broad empiric therapy, which is linked to increased mortality, LOS, superinfections, and disruption of microbiota leading to AMR [71, 72].”
Prospective Evaluation of a Rapid Clinical Metagenomics Test for Bacterial Pneumonia
Mu, S., Hu, L., Zhang, Y., Liu, Y., Cui, X., Zou, X., Wang, Y., Lu, B., Zhou, S., Liang, X., et al. (2021) · Frontiers in Cellular and Infection Microbiology · doi:10.2139/ssrn.3779202 · Cited by 45
Silva, P. G. O. E., Filho, L. A. C. B., Flores, I. P., Silva, V. V. E., Maciel, A. T., & Medeiros, L. S. (2023) · Medwave · doi:10.5867/medwave.2023.11.2719 · Cited by 36
Hao, J., Li, W., Wang, Y., Zhao, J., & Chen, Y. (2023) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2023.1271952 · Cited by 34
“However, as a double-edged sword, EAT that is too broad also leads to abuses of antibiotics and selectiveresistanceofpathogens(Jainetal.,2015),eventuallyimpairing patients ’ prognosis (Webb et al., 2019).”
BackgroundElias, C., Nunes, M. C., & Saadatian‐Elahi, M. (2024) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000001005 · Cited by 34
Emergency medicine updates: Management of sepsis and septic shock
Long, B., & Gottlieb, M. A. (2025) · The American Journal of Emergency Medicine · doi:10.1016/j.ajem.2025.01.054 · Cited by 34
Lin, Q., Yao, Y., Li, X., Zhang, S., Guo, H., Ma, X., Chen, W., Ru, C., Wang, L., Wang, B., et al. (2023) · Scandinavian Journal of Infectious Diseases · doi:10.1080/23744235.2023.2276785 · Cited by 34
“Delayed aetiological diagnosis can result in inappropriate empirical broad-spectrum antibiotic treatment, leading to poor treatment outcomes, prolonged hospital stays, and increased medical expenses [24].”
BackgroundOveruse of Broad-Spectrum Antibiotics for Pneumonia
Klompas, M. (2020) · JAMA Internal Medicine · doi:10.1001/jamainternmed.2019.7251 · Cited by 34
Hemithioindigo‐Based Visible Light‐Activated Molecular Machines Kill Bacteria by Oxidative Damage
Santos, A. L., van Venrooy, A. R., Reed, A. K., Wyderka, A. M., García‐López, V., Alemany, L. B., Oliver, A., Tegos, G. P., & Tour, J. M. (2022) · Advanced Science · doi:10.1002/advs.202203242 · Cited by 29
Wang, H.-C., Tsai, M.-H., Chu, S., Liao, C.-C., Lai, M., Huang, H., Chiang, M., Fu, R.-H., & Hsu, J. (2021) · BMC Infectious Diseases · doi:10.1186/s12879-021-06673-9 · Cited by 28
Metlay, J. P., & WATERER, G. W. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000671 · Cited by 28
Antibiotic use in children hospitalised with pneumonia in Central Vietnam
Nguyen, P. T. K., Tran, H. T., Fitzgerald, D. A., Graham, S. M., & Marais, B. J. (2020) · Archives of Disease in Childhood · doi:10.1136/archdischild-2019-317733 · Cited by 26
Validation of a Prediction Score for Drug-Resistant Microorganisms in Community-acquired Pneumonia
Ceccato, A., Méndez, R., Ewig, S., de la Torre, M. C., Cillóniz, C., Gabarrús, A., Prina, E., Ranzani, O., Ferrer, M., Almirall, J., et al. (2020) · Annals of the American Thoracic Society · doi:10.1513/annalsats.202005-558oc · Cited by 25
Voiriot, G., Argaud, L., Cohen, Y., Tuffet, S., Chauvelot, L., Souweine, B., Klouche, K., Reignier, J., Schwebel, C., Rouzé, A., et al. (2025) · Intensive Care Medicine · doi:10.1007/s00134-025-08014-9 · Cited by 25
Advances in community-acquired pneumonia
Jones, B. E., & WATERER, G. W. (2020) · Therapeutic Advances in Infectious Disease · doi:10.1177/2049936120969607 · Cited by 24
Wang, H.-C., Liao, C.-C., Chu, S., Lai, M., Huang, H., Chiang, M., Fu, R.-H., Hsu, J., & Tsai, M.-H. (2020) · Antibiotics · doi:10.3390/antibiotics9110760 · Cited by 23
“Limited-spectrum antibiotic treatments are defined as the use of ampicillin/sulbactam, oxacillin, ceftriaxone, or gentamicin [24].”
BackgroundXu, R., Wu, L., Wu, L., Xu, C., & Mu, T. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1253520 · Cited by 22
“In line with these concerns, current treatment guidelines emphasize a no antibiotic prescribing strategy for the majority of self-limiting RTIs, as evidence suggests that reducing antibiotic prescribing does not compromise patient safety regarding bacterial infections (Gerber et al., 2017; Webb et al., 2019a).”
BackgroundShin, D. H., Kim, H.-S., Heo, E., Shin, M. J., Kim, K.-H., Lee, H., Park, J. S., Park, K. U., Jung, J., Song, K., et al. (2022) · Microbiology Spectrum · doi:10.1128/spectrum.00335-22 · Cited by 20
Pereira, B. R. A., Dias, L. M. F., Bezerra, J. L., de Sá, L. L. F., de Ferreira, W. F., & Vieira, J. F. P. D. N. (2022) · Research Society and Development · doi:10.33448/rsd-v11i8.30875 · Cited by 19
Pattern of Antibiotic Use among Hospitalized Patients at a Level One Multidisciplinary Care Hospital
Hodoșan, V., Daina, L., Zaha, D. C., Cotrău, P., Vladu, A., Dorobanțu, F. R., Negrău, M. O., Babeş, E. E., Babeş, V. V., & Daina, C. M. (2023) · Healthcare · doi:10.3390/healthcare11091302 · Cited by 19
Identify Drug-Resistant Pathogens in Patients with Community-Acquired Pneumonia
Amati, F., Bindo, F., Stainer, A., Gramegna, A., Mantero, M., Nigro, M., Bussini, L., Bartoletti, M., Blasi, F., & Aliberti, S. (2023) · Advances in respiratory medicine · doi:10.3390/arm91030018 · Cited by 18
Zhang, S., Li, X., Li, X., Fu, Y., Chen, L., Wang, W., Lin, Q., Lou, H. P., Yao, Y., Chen, W., et al. (2025) · EBioMedicine · doi:10.1016/j.ebiom.2025.105752 · Cited by 17
“16 Therefore, rapid and accurate diagnosis is crucial for the targeted use of antibiotics and for improving treatment outcomes, and research on technologies of rapid pathogen diagnose has been a global hot topic in recent years.”
Baker, K. R., Flentie, K., Spears, B. R., Mozharov, S., Roberts, K., ganbour, A. E., Somers, M., Calkwood, J., Liu, J., DaPonte, K., et al. (2023) · Journal of Clinical Microbiology · doi:10.1128/jcm.00546-23 · Cited by 16
“accuracy, reproducibility, and time-to-results (TTRs) of this system in a multicenter evaluation.”
BackgroundLing, L., Lai, C. K. C., & Rhee, C. (2025) · Thorax · doi:10.1136/thorax-2024-222297 · Cited by 16
“8 31 32 As such, there is an urgent need to overcome the diagnostic limitations of conventional cultures for bacterial pathogens to improve the management of pneumonia.”
Gil, R., & Webb, B. J. (2020) · Current Opinion in Pulmonary Medicine · doi:10.1097/mcp.0000000000000670 · Cited by 16
Self-citationUmpleby, H., Dushianthan, A., Catton, T., & Saeed, K. B. A. (2022) · Journal of Emergency and Critical Care Medicine · doi:10.21037/jeccm-22-6 · Cited by 17
“A retrospective study of 1,995 adult patients admitted to four hospitals in the United States with CAP found despite adjustment for multiple confounders broad-spectrum antibiotics were associated with increased mortality (OR 4.6, 95% CI: 2.9–7.5; P<0.001) (61) ( Table 1 ).”
InfluentialInterventions to improve outcomes in community-acquired pneumonia
Cillóniz, C., Pericàs, J. M., & Curioso, W. H. (2023) · Expert Review of Anti-infective Therapy · doi:10.1080/14787210.2023.2257392 · Cited by 16
“Aspects such as the severity of CAP or the virulence of certain microorganisms should also be considered when deciding the type of antimicrobials, route of administration, dose and posology [107,110].”
BackgroundInfluentialBest practice: antibiotic decision-making in ICUs
Brink, A. J., & Richards, G. A. (2020) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000752 · Cited by 16
Carr, J. R., Jones, B. E., Collingridge, D. S., Webb, B. J., Vines, C. G., Zobell, B., Allen, T. L., Srivastava, R., Rubin, J., & Dean, N. C. (2020) · The Journal of Rural Health · doi:10.1111/jrh.12543 · Cited by 16
Self-citationBaghdadi, J. D., Goodman, K. E., Magder, L. S., Claeys, K. C., Sutherland, M. E., & Harris, A. D. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf039 · Cited by 15
Lai, Y. R., Lan, X., Qin, Y., Wei, Y., Li, X., Feng, J., & Jiang, J. (2024) · Archives of Microbiology · doi:10.1007/s00203-024-04184-0 · Cited by 14
“…bacteria such as Clostridium difficile , Staphylococcus aureus , and Clostridium perfringens have colonized the intestines in large numbers, resulting in an imbalance in the diversity of intestinal microorganisms, and thus causing antibiotic-associated diarrhea (Webb et al. 2019; Nies et al. 2022).”
Risk Factors and Outcomes Associated With Polymicrobial Infection in Community-Acquired Pneumonia
Cillóniz, C., Calabretta, D., Palomeque, A. C., Gabarrús, A., Ferrer, M., Marcos, M. Á., & Torres, A. (2025) · Archivos de Bronconeumología · doi:10.1016/j.arbres.2025.01.001 · Cited by 13
Chang, C.-M., Hsieh, M., Yang, C., How, C., Chen, P., & Meng, Y.-H. (2023) · Clinical Microbiology and Infection · doi:10.1016/j.cmi.2023.01.004 · Cited by 13
Cartuliares, M. B., Søgaard, S. N., Rosenvinge, F. S., Mogensen, C. B., Hertz, M. I., & Skjøt‐Arkil, H. (2023) · Antibiotics · doi:10.3390/antibiotics12121680 · Cited by 13
A review of the value of point-of-care testing for community-acquired pneumonia
Palomeque, A. C., Cillóniz, C., Soler-Comas, A., Canseco, J., Rovira-Ribalta, N., Motos, A., & Torres, A. (2024) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2024.2391027 · Cited by 13
“Indeed, empirical broad-spectrum antibiotics are initiated in approximately 30% of patients with CAP, which has been associated with poor outcomes in CAP, including increased mortality [21,22].”
Hatton, C., Quarton, S., Livesey, A., Alenazi, B. A., Jeff, C., & Sapey, E. (2025) · BMJ Open · doi:10.1136/bmjopen-2025-099100 · Cited by 12
“While these studies are also at serious risk of bias, predominantly due to confounding, the extent to which this impacts the observed results is likely less than that for clinical outcomes as the relationship between intervention and outcome is more direct.”
Kobayashi, H., Shindo, Y., Kobayashi, D., Sakakibara, T., Murakami, Y., Yagi, M., Matsuura, A., Sato, K., Matsui, K., Emoto, R., et al. (2022) · International Journal of Infectious Diseases · doi:10.1016/j.ijid.2022.09.015 · Cited by 12
Benis, A., & Tamburis, O. (2023) · Yearbook of Medical Informatics · doi:10.1055/s-0043-1768717 · Cited by 12
Optimal antibiotic use in the intensive care unit
Micek, S. T., Vazquez Guillamet, M. C., Reynolds, D., Matuszak, S., Kolodziej, L., & Kollef, M. H. (2025) · Critical Care · doi:10.1186/s13054-025-05653-8 · Cited by 11
“Clinicians tend to overestimate the likelihood of resistant bacteria, especially in community-onset sepsis, leading to overly broad antibiotics, increasing antibiotic resistance risk and mortality [32, 33].”
Hsu, J., Chu, S., Wang, H.-C., Liao, C.-C., Lai, M., Huang, H., Chiang, M., Fu, R.-H., & Tsai, M.-H. (2021) · Antibiotics · doi:10.3390/antibiotics10040459 · Cited by 11
“The following first-line antibiotics, namely ampicillin/sulbactam, oxacillin, ceftriaxone, and gentamicin, were defined as limited-spectrum antibiotic therapy [23].”
BackgroundCurrent opinion in management of septic shock due to Gram-negative bacteria
Tabah, A., Buetti, N., Barbier, F., & Timsit, J. (2021) · Current Opinion in Infectious Diseases · doi:10.1097/qco.0000000000000767 · Cited by 11
Timing and Spectrum of Antibiotic Treatment for Suspected Sepsis and Septic Shock
Pak, T. R., Rhee, C., & Klompas, M. (2022) · Infectious Disease Clinics of North America · doi:10.1016/j.idc.2022.08.001 · Cited by 11
Saravolatz, L. I. I., Gandhi, T. N., Vaughn, V. M., Ratz, D., Horowitz, J. K., Gupta, A. B., McLaughlin, E. S., Czilok, T., Weinmann, A. J., Paje, D. G., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf344 · Cited by 10
Bono, K. R., Caceda, J. A., Zhai, M., Horng, H., Goldstein, C., Sifri, Z. C., Cennimo, D. J., & Glass, N. E. (2022) · Journal of Surgical Research · doi:10.1016/j.jss.2022.11.054 · Cited by 10
Treatment Heterogeneity in Pseudomonas aeruginosa Pneumonia
Caffrey, A. R., Appaneal, H. J., Liao, J. X., Piehl, E. C., Lopes, V., & Puzniak, L. (2022) · Antibiotics · doi:10.3390/antibiotics11081033 · Cited by 10
Emerging Resistance of Gram Negative Pathogens in Community-Acquired Pneumonia
Amati, F., & Restrepo, M. I. (2020) · Seminars in Respiratory and Critical Care Medicine · doi:10.1055/s-0040-1709137 · Cited by 10
When should I start broad-spectrum antibiotics?
Timsit, J., Depuydt, P. O., & Kanj, S. S. (2024) · Intensive Care Medicine · doi:10.1007/s00134-024-07654-7 · Cited by 10
Streva, V. A., Gajewski, J., Pento, J., Chandrasekaran, A., Green, M., Lindley, J. M., Huband, M. D., ganbour, A. E., Roberts, K., Flentie, K., et al. (2025) · Journal of Clinical Microbiology · doi:10.1128/jcm.01819-24 · Cited by 9
Gaston, D. C., Humphries, R. M., Lewis, A. A., Gatto, C. L., Wang, L., Nelson, G. E., Stollings, J. L., Ereshefsky, B. J., Christensen, M. A., Dear, M. L., et al. (2025) · Clinical Infectious Diseases · doi:10.1093/cid/ciaf677 · Cited by 9
Severe community-acquired pneumonia in the post COVID-19 era
Ruiz-Spinelli, A., WATERER, G. W., & Rello, J. (2023) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000001083 · Cited by 9
Monocyte Activation: The Link between Obstructive Sleep Apnea and Cardiovascular Disease?
Borker, P. V., & Patel, S. R. (2022) · American Journal of Respiratory and Critical Care Medicine · doi:10.1164/rccm.202201-0215ed · Cited by 9
Ukai, T., Maruyama, T., Tomioka, S., Fukui, T., Matsuda, S., Fushimi, K., & Iso, H. (2023) · Heliyon · doi:10.1016/j.heliyon.2023.e22303 · Cited by 8
“This misestimation of MDR pathogens can cause the overuse of antibiotics leading to adverse outcomes [9,10].”
BackgroundTsoumbris, P. R., Vincent, R. M., & Jaschke, P. R. (2024) · Archives of Virology · doi:10.1007/s00705-024-06170-9 · Cited by 8
Besien, R. F. V., Hampton, N. B., Micek, S. T., & Kollef, M. H. (2022) · Medicine · doi:10.1097/md.0000000000029159 · Cited by 8
“[8] The rise of MDR organisms in CAP is reflected in current prescribing patterns for initial antibiotic therapy of CAP.”
BackgroundInfluentialShiroshita, A., Miyakoshi, C., Tsutsumi, S., Shiba, H., Shirakawa, C., Sato, K., Matsushita, S., Kimura, Y., Tomii, K., Ohgiya, M., et al. (2021) · Scientific Reports · doi:10.1038/s41598-021-99640-y · Cited by 8
Krueger, C., Nguyen, E. L., Mahant, S., Borkhoff, C. M., Cichon, J., Drouin, O., Pound, C., Quet, J., Wahi, G., Bayliss, A., et al. (2024) · Archives of Disease in Childhood · doi:10.1136/archdischild-2023-326175 · Cited by 7
Chen, X., Chen, W., Zhou, J., Chen, J., Cao, G., Huang, C., Lu, X., Chen, X., Luo, R., Huang, H., et al. (2025) · Virulence · doi:10.1080/21505594.2025.2509757 · Cited by 7
“Unnecessary and inappropriate antibiotic use may lead to adverse side effects and contribute to bacterial resistance [21,37].”
Huan, X., Hu, L., Li, H., Yu, F., & Shao, H. (2025) · International Journal of Antimicrobial Agents · doi:10.1016/j.ijantimicag.2025.107632 · Cited by 7
Taniguchi, J., Aso, S., Matsui, H., Fushimi, K., & Yasunaga, H. (2025) · Journal of Hospital Medicine · doi:10.1002/jhm.70195 · Cited by 7
“25 26 Because the concept of NHCAP is rooted in HCAP and both entities employ similar criteria, the NHCAP category itself may also be beset by limitations in predicting antibiotic ‐ resistant pathogens, even in settings with aging populations and frequent healthcare exposure such as Japan.”
Safety considerations of current drug treatment strategies for nosocomial pneumonia
Ceccato, A., Giannatale, P. D., Nogas, S., & Torres, A. (2021) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2021.1857362 · Cited by 7
Song, J., & Lee, J. H. (2023) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2023.115 · Cited by 7
Wei, J., Uppal, A., Nganjimi, C., Warr, H., Ibrahim, Y., Gu, Q., Yuan, H., Rahman, N. M., Jones, N., Walker, A. S., et al. (2024) · Journal of Infection · doi:10.1016/j.jinf.2024.106161 · Cited by 7
Sellés, N. A., Gallego, M., Font, J., Vallés, J., Morón, A., Monsó, E., & Rello, J. (2020) · BMC Pulmonary Medicine · doi:10.1186/s12890-020-1115-0 · Cited by 7
“However, antipseudomonal antibiotics are considered as broad spectrum and, due to their potential for causing collateral damage [10, 11], their administration should be restricted.”
BackgroundMishima, Y., Nawa, N., Asada, M., Nagashima, M., Aiso, Y., Nukui, Y., Fujiwara, T., & Shigemitsu, H. (2023) · Critical Care Explorations · doi:10.1097/cce.0000000000000837 · Cited by 6
“Drug-related adverse events have been reported to occur in greater than 15% of hospitalized patients, and antibiotics are one of the most common causative drugs (24, 25).”
BackgroundYoung, E. L., Roach, D., Martinsen, M. A., McGrath, G., Holbrook, N., Cho, H., Seyoum, E. Y., Pierce, V., & Bhattacharyya, R. P. (2024) · Journal of Clinical Microbiology · doi:10.1128/jcm.00997-24 · Cited by 6
Dessajan, J., Berti, V., Armand-Lefèvre, L., Voiriot, G., Fartoukh, M. S., & Timsit, J. (2025) · Expert Review of Molecular Diagnostics · doi:10.1080/14737159.2025.2527635 · Cited by 6
“Recent studies [7,61,62] underscore the importance of balancing appropriate antibiotic use with the risks of resistance and suboptimal treatment.”
Chen, G., Li, W., Zhao, Y., Cui, Y., Song, C., Li, H., Liu, B., Li, Y., & Pan, P. (2025) · Scientific Reports · doi:10.1038/s41598-025-26212-9 · Cited by 6
Pseudomonas aeruginosa in Patients With Nosocomial Respiratory Infections
Serrano-Mayorga, C. C., Olivella-Gómez, J., Sanabria-Herrera, N., Nseir, S., Torres, A., Martín‐Loeches, I., Reyes, L. F., Ranzani, O., Póvoa, P. M. S. R., Díaz, E., et al. (2026) · CHEST Journal · doi:10.1016/j.chest.2025.12.033 · Cited by 6
Carr, J. R., Knox, D., Butler, A. M., Lum, M. M., Jacobs, J. R., Jephson, A. R., Jones, B. E., Brown, S. M., & Dean, N. C. (2023) · Critical Care Medicine · doi:10.1097/ccm.0000000000006163 · Cited by 6
Self-citationColmerauer, J. L., Linder, K. E., Dempsey, C. J., Kuti, J. L., Nicolau, D. P., & Bilinskaya, A. (2021) · Hospital Pharmacy · doi:10.1177/00185787211055797 · Cited by 6
Cillóniz, C., & Torres, A. (2023) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2023.2261376 · Cited by 6
“some antibiotics are all factors that contribute to the unmet needs for new antibiotics for CAP [13,16].”
BackgroundThe challenge of antimicrobial prescribing for hospital-acquired pneumonia
Wootton, D. G., Aston, S., & Felton, T. (2019) · Journal of Hospital Infection · doi:10.1016/j.jhin.2019.11.002 · Cited by 6
“NICE bemoans the lack of evidence to support their recommendations, and these frustrations echo the sentiments of recent American and European HAP guidelines [5,6].”
BackgroundModgil, V., Shafiq, N., Gondara, A., Surial, R., Singh, H., Karol, V., Kaur, M., Lambert, H., & Taneja, N. (2025) · Indian Journal of Medical Microbiology · doi:10.1016/j.ijmmb.2025.100829 · Cited by 5
Essential components of a definition for early antibiotic treatment failure: A scoping review
Iwata, H., Kaneko, M., Aoki, T., Endo, K., Nagai, Y., Kanto, K., Yao, M., & Hamada, S. (2023) · PLoS ONE · doi:10.1371/journal.pone.0283417 · Cited by 5
“Effective EATF evaluation may help prevent unnecessary changes to broad-spectrum antibiotics, lower the risk of Clostridium difficile colitis, prevent the development of multidrug-resistant bacteria, and improve mortality [14, 15].”
BackgroundTakazono, T., Hosogaya, N., Saito, Y., Takemura, M., Iwanaga, N., Sakamoto, N., Hirayama, J., Ueno, R., & Mukae, H. (2025) · Infectious Diseases and Therapy · doi:10.1007/s40121-025-01142-1 · Cited by 5
Sekandarzad, A., Flügler, A., Rheinboldt, A., Rother, D., Först, G., Rieg, S., Supady, A., Lother, A., Staudacher, D. L., Wengenmayer, T., et al. (2025) · Frontiers in Medicine · doi:10.3389/fmed.2025.1549355 · Cited by 5
Deshpande, A., Walker, R. E., Schulte, R. J., Pallotta, A. M., Tereshchenko, L. G., Hu, B., Kadri, S. S., Klompas, M., & Rothberg, M. B. (2023) · Trials · doi:10.1186/s13063-023-07615-3 · Cited by 5
Eosinopenia and prognosis in severe community-acquired pneumonia
Cillóniz, C., Castañeda, T., Campanella, A., Guglielmi, R., Gabarrús, A., Granero, S., Calvo-García, C., Marcos, M. Á., & Torres, A. (2026) · Pneumonia · doi:10.1186/s41479-026-00196-0 · Cited by 4
“Missing data were handled using multiple imputations [27, 28].”
Koga, S., Takazono, T., Kido, T., Muramatsu, K., Tokutsu, K., Tokito, T., Okuno, D., Ito, Y., Yura, H., Takeda, K., et al. (2023) · Microorganisms · doi:10.3390/microorganisms11081905 · Cited by 4
“Several previous reports have questioned the empirical use of broad-spectrum antimicrobial agents, including anti-MRSA agents, in community-acquired pneumonia [5,19].”
BackgroundAntibiotics: it is all about timing, isn’t it?
Klompas, M., & Rhee, C. (2022) · Current Opinion in Critical Care · doi:10.1097/mcc.0000000000000969 · Cited by 4
Metadata
- Authors
- Webb, B. J., Sorensen, J., Jephson, A., Mecham, I., & Dean, N. C.
- Affiliations
- Intermountain Healthcare (US)
- Venue
- European Respiratory Journal
- Publisher
- European Respiratory Society (ERS)
- Published
- 2019-04-25
- Volume
- 54
- Issue
- 1
- Pages
- 1900057
- ISSN
- 0903-1936 (ISSN-L)
- 1399-3003
- OpenAlex
- W2941945808
- Cited by
- 164
- References
- 40
- Citations by year
- 2026: 17 · 2025: 32 · 2024: 24 · 2023: 28 · 2022: 20 · 2021: 21 · 2020: 18 · 2019: 4
- FWCI
- 11.98
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- European Respiratory Journal (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Intermountain Research and Medical Foundation
- Topics
- Health Sciences › Medicine › Epidemiology › Pneumonia and Respiratory Infections
- Health Sciences › Medicine › Infectious Diseases › Antibiotic Use and Resistance
- Health Sciences › Medicine › Critical Care and Intensive Care Medicine › Nosocomial Infections in ICU
- Keywords
- broad-spectrum antibiotics, community-onset pneumonia, 30-day mortality, Clostridium difficile infection, healthcare-associated pneumonia, length of hospital stay, health care costs, drug-resistant pathogens, emergency department admission, propensity score weighting
- MeSH terms
- Aged, Anti-Bacterial Agents, Clostridium Infections, Female, Humans, Length of Stay, Male, Middle Aged, Pneumonia, Retrospective Studies, Time Factors, Utah, Multivariate Analysis, Linear Models, Databases, Factual, Community-Acquired Infections, Drug Resistance, Bacterial, Propensity Score
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.